AU772435B2 - Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester - Google Patents

Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester Download PDF

Info

Publication number
AU772435B2
AU772435B2 AU14364/00A AU1436400A AU772435B2 AU 772435 B2 AU772435 B2 AU 772435B2 AU 14364/00 A AU14364/00 A AU 14364/00A AU 1436400 A AU1436400 A AU 1436400A AU 772435 B2 AU772435 B2 AU 772435B2
Authority
AU
Australia
Prior art keywords
composition
weight percent
propylene glycol
weight
hydrocortisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU14364/00A
Other languages
English (en)
Other versions
AU1436400A (en
Inventor
Gunilla Lekare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU772435(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir AB filed Critical Medivir AB
Publication of AU1436400A publication Critical patent/AU1436400A/en
Application granted granted Critical
Publication of AU772435B2 publication Critical patent/AU772435B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU14364/00A 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester Expired AU772435B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803929 1998-11-18
SE9803929A SE9803929D0 (sv) 1998-11-18 1998-11-18 Antiviral formulation
PCT/SE1999/002043 WO2000029027A1 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester

Publications (2)

Publication Number Publication Date
AU1436400A AU1436400A (en) 2000-06-05
AU772435B2 true AU772435B2 (en) 2004-04-29

Family

ID=20413320

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14364/00A Expired AU772435B2 (en) 1998-11-18 1999-11-12 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester

Country Status (21)

Country Link
EP (1) EP1131104B1 (enExample)
JP (2) JP2002529520A (enExample)
KR (1) KR100608963B1 (enExample)
CN (1) CN1160128C (enExample)
AR (1) AR023705A1 (enExample)
AT (1) ATE288283T1 (enExample)
AU (1) AU772435B2 (enExample)
CA (1) CA2351463C (enExample)
DE (1) DE69923584T2 (enExample)
DK (1) DK1131104T3 (enExample)
EG (1) EG23853A (enExample)
ES (1) ES2233104T3 (enExample)
HK (1) HK1042440B (enExample)
IL (2) IL142702A0 (enExample)
MY (1) MY122397A (enExample)
NZ (1) NZ511832A (enExample)
PT (1) PT1131104E (enExample)
SE (1) SE9803929D0 (enExample)
TW (1) TW589191B (enExample)
WO (1) WO2000029027A1 (enExample)
ZA (1) ZA200103335B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100956369B1 (ko) * 2001-11-19 2010-05-10 메디진 아게 바이러스성 피부 질환 및 종양 질환 치료용 약제
ZA200602544B (en) 2003-10-09 2007-06-27 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
JP4972062B2 (ja) * 2008-03-17 2012-07-11 メディヴィル・アクチエボラーグ 抗ウイルス製剤
ES2955089T3 (es) * 2018-08-17 2023-11-28 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Composición tópica estable en fase que comprende aciclovir e hidrocortisona

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024355A1 (en) * 1995-02-06 1996-08-15 Astra Aktiebolag Novel pharmaceutical combination
WO1998017316A1 (en) * 1996-10-18 1998-04-30 Cellegy Pharmaceuticals Inc. Potent transdermal penetration enhancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024355A1 (en) * 1995-02-06 1996-08-15 Astra Aktiebolag Novel pharmaceutical combination
WO1998017316A1 (en) * 1996-10-18 1998-04-30 Cellegy Pharmaceuticals Inc. Potent transdermal penetration enhancers

Also Published As

Publication number Publication date
HK1042440A1 (en) 2002-08-16
EG23853A (en) 2007-11-06
AU1436400A (en) 2000-06-05
TW589191B (en) 2004-06-01
CN1326364A (zh) 2001-12-12
DK1131104T3 (da) 2005-03-14
ES2233104T3 (es) 2005-06-01
IL142702A (en) 2006-07-05
HK1042440B (zh) 2005-04-29
EP1131104B1 (en) 2005-02-02
ZA200103335B (en) 2002-07-24
MY122397A (en) 2006-04-29
NZ511832A (en) 2003-09-26
ATE288283T1 (de) 2005-02-15
CN1160128C (zh) 2004-08-04
CA2351463C (en) 2009-10-13
DE69923584T2 (de) 2006-03-23
JP2002529520A (ja) 2002-09-10
IL142702A0 (en) 2002-03-10
KR20010075720A (ko) 2001-08-09
PT1131104E (pt) 2005-03-31
EP1131104A1 (en) 2001-09-12
WO2000029027A1 (en) 2000-05-25
JP5420583B2 (ja) 2014-02-19
SE9803929D0 (sv) 1998-11-18
CA2351463A1 (en) 2000-05-25
AR023705A1 (es) 2002-09-04
JP2011157392A (ja) 2011-08-18
KR100608963B1 (ko) 2006-08-09
DE69923584D1 (de) 2005-03-10

Similar Documents

Publication Publication Date Title
US5869529A (en) Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
EP0044543B1 (en) Topical formulations of 9-(2-hydroxyethoxymethyl) guanine
WO1996002244A1 (en) A topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
US4963555A (en) Formulations of heterocyclic compounds
US20170020882A1 (en) Antiviral formulation
US7223387B2 (en) Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
WO1998010768A1 (en) Antiviral compositions
WO1997034607A1 (en) Topical formulations of aciclovir
JP5420583B2 (ja) プロピレングリコールおよびアルカン酸イソプロピルエステルを含む抗ウイルス製剤
EP3836934B1 (en) Phase stable topical composition comprising acyclovir and hydrocortisone
MXPA01005020A (en) Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
SA99200836B1 (ar) صيغ مضادة للفيروسات antiviral formulations تتضمن propylene glycol واستر أيزويروبيلي لحمض الكانوي isopropyl alkanoic acid ester
EP0787490A1 (en) A topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
TR2021002170T2 (tr) Faz ayrişmasi olmayan asi̇klovi̇r ve hi̇drokorti̇zon i̇çeren topi̇kal formülasyon

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired